NurOwn Phase 2 Clinical Trial Results Promising, BrainStorm Cell Reports
BrainStorm Cell Therapeutics recently presented data from its Phase 2 clinical trial, showing that the company’s NurOwn stem cells technology may halt disease progression in patients with amyotrophic lateral sclerosis (ALS). The data were presented at the 27th International Symposium on ALS/MND in Dublin, Ireland. The multi-center, randomized, double blind, placebo-controlled,…